Patents Issued in October 1, 2020
  • Publication number: 20200306282
    Abstract: Provided herein is a composition comprising eriocitrin, and uses thereof for managing pre-diabetes and diabetes. The composition may be useful for increasing GLP-1 levels.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Inventors: Robert M. BREWSTER, Thais CESAR, Carolina Barbosa RIBEIRO
  • Publication number: 20200306283
    Abstract: There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours post-primary treatment: a) a first therapeutic agent effective against cancer stem cells, such as a cytotoxic chemotherapy; and b) a second therapeutic agent that disrupts a downstream effect of a tissue repair signalling cascade induced by the primary treatment, including an inhibitor of neu-1 sialidase such as oseltamivir phosphate, or an inhibitor of at least one cytokine associated with stem cell enrichment such as HGF, IL-6, TGF-beta, PGE-2 or PDGF-BB. There is also provided a cancer treatment with chemotherapy agent, such as a checkpoint inhibitor, in combination with either a neuraminidase 1 inhibitor such as oseltamivir phosphate, or a COX-2 inhibitor such as celecoxib, or both.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 1, 2020
    Inventors: William Warren HARLESS, Myron SZEWCZUK
  • Publication number: 20200306284
    Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 1, 2020
    Inventors: Samir Mitragotri, Marta Broto, Kathryn M. Camacho, Stefano Menegatti
  • Publication number: 20200306285
    Abstract: The invention is directed to a method for treating a cancer patient by administering an agent that depletes intracellular ATP along with a purine analog, such as fludarabine. It is also directed to a method for selecting a patient having cancer cells susceptible to depletion of their intracellular ATP.
    Type: Application
    Filed: September 27, 2019
    Publication date: October 1, 2020
    Applicants: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
    Inventors: Atef NEHDI, Mohamed BOUDJELAL, Ahmed ALASKAR
  • Publication number: 20200306286
    Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 1, 2020
    Inventors: Morag Helen STEWART, Catherine CIFUENTES-ROJAS, Ki Young PAEK, Avak KAHVEJIAN, Nicholas McCartney PLUGIS, Alexandra Sophie DE BOER, Erica Gabrielle WEINSTEIN, Sebastian TROUSIL
  • Publication number: 20200306287
    Abstract: The present invention provides a hemostatic powder. The hemostatic powder is mainly present in the form of a columnar particle, wherein the ratio of axial length to diameter of the columnar particle is less than 5; the hemostatic powder includes a polymer represented by the following structural formula: wherein the R is at least one selected from the group consisting of —NH2, —OCH2CH2OH, —OCH2CH2CH2OH, —OH, —ONa, —OK and —OCa; m, n and p respectively represent number percentages of corresponding repeating units in polymer molecules, and satisfy the following equations: m+n+p=1, p/(m+n+p)=0.05˜0.
    Type: Application
    Filed: October 25, 2017
    Publication date: October 1, 2020
    Inventors: Yingshan ZHOU, Rui JIANG, Zuguang GONG, Liqin XU, Shiming ZHOU, Xiaoming ZHOU
  • Publication number: 20200306288
    Abstract: The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 1, 2020
    Applicant: JOINTHERAPEUTICS S.R.L.
    Inventors: Lanfranco Callegaro, Paola BRUN, Giulio Bianchini
  • Publication number: 20200306289
    Abstract: Provided is a formulation including chitosan impregnated with a modified clay. The modified clay is a smectite clay modified with cations. The formulation is effective for healing a burn wound. It is superior in skin regeneration and patient comfort than commonly available clinical treatments. The formulation can be used for the treatment of dermal wounds including burn, incision, excision, and abrasion wounds.
    Type: Application
    Filed: March 24, 2020
    Publication date: October 1, 2020
    Applicant: COMSATS UNIVERSITY ISLAMABAD
    Inventors: Fazli WAHID, Taous KHAN, Naveera NAEEM
  • Publication number: 20200306290
    Abstract: Embodiments of the present disclosure are directed to compositions, and in particular beverages, containing a blend of natural ingredients that, together, lower blood pressure when consumed regularly over a period of time. The natural ingredients may include beet root, pomegranate juice or puree, hibiscus, tart cherry juice or puree, and cranberry juice or puree. The beverage is formulated for taste and mouthfeel, as well as for effectiveness in lowering blood pressure. Embodiments of the present invention are also directed to methods of lowering blood pressure—systolic, diastolic, or both—by providing the beverage disclosed herein and instructing an individual to consume a serving of the beverage once per day for a period of time, for instance at least two weeks.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Ira H. Antelis, Susan Schachter
  • Publication number: 20200306291
    Abstract: Compositions comprising a citrate salt and a calcium carbonate-containing material, articles-of-manufacturing and kits comprising same and uses thereof for inducing blood coagulation and/or for reducing or arresting hemorrhaging, particularly internal hemorrhaging, are disclosed.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: Ariel-University Research and Development Company Ltd.
    Inventors: Danny BARANES, Ayala GANCZ, Yekaterina ZUEV, Liat HAMMER
  • Publication number: 20200306292
    Abstract: A method of treating acute hypovolemia due to one or more medical conditions including sepsis with shock, hemorrhagic shock, burn injury, nephritic syndrome, and multiorgan failure by injecting an aqueous solution of hypochlorous acid to a patient in need thereof.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 1, 2020
    Applicant: Wonder Spray, LLC
    Inventor: John Burd
  • Publication number: 20200306293
    Abstract: The use of ferric maltol compositions for the treatment or prevention of cancer and tumours is disclosed, in particular for the treatment or prevention of gastrointestinal cancers or gastrointestinal tumours, such as large bowel (colorectal), small bowel or upper gastrointestinal cancers.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 1, 2020
    Inventors: Jonathan Joseph POWELL, Dora I.A. PEREIRA
  • Publication number: 20200306294
    Abstract: Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Steven J. Oldenburg, Martin Miranda, David S. Sebba, Todd J. Harris
  • Publication number: 20200306295
    Abstract: Confronted with the rapid evolution and dissemination of antibiotic resistance, there is an urgent need to develop alternative treatment strategies for drug-resistant S. aureus, especially for methicillin-resistant S. aureus (MRSA). We report a photonic approach to eradicate MRSA through blue-light photolysis of staphyloxanthin (STX), an anti-oxidative carotenoid acting as the constituent lipid of the functional membrane microdomains of S. aureus. Our transient absorption imaging study and mass spectrometry unveil the photolysis process of STX. After effective STX photolysis by pulsed laser, cell membranes are found severely disorganized and malfunctioned to defense antibiotics, as unveiled by membrane permeabilization, membrane fluidification, and detachment of membrane protein, PBP2a.
    Type: Application
    Filed: September 24, 2019
    Publication date: October 1, 2020
    Applicant: Purdue Research Foundation
    Inventors: Ji-xin Cheng, Mohamed Seleem, Pu-Ting Dong, Jie Hui
  • Publication number: 20200306296
    Abstract: Exosomes are generated from host embryonal carcinoma or embryonic progenitor cell lines and used for induced tissue regeneration. These inventive compositions and methods provide for induced tissue regeneration in aged or diseased mammalian tissues in vivo without the use of transgenically-expressed genes. Cells are reprogrammed to a prenatal, indeed a pre-fetal state, as indicated by for example in the case of many stromal cell types, by a decrease in the markers ADIRF and COX7A1.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: AgeX Therapeutics, Inc.
    Inventors: Michael West, Dana Larocca, Jieun Lee
  • Publication number: 20200306297
    Abstract: Vesicular stomatitis virus glycoprotein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes by gene transfection and fluorescence tracking. VSVG pseudotyping of exosomes does not affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG without the ectodomain integrate into the exosomal membrane, suggesting that the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-length VSVG are internalized by multiple-recipient cell types to a greater degree compared to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain in cell tropism.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Biao Lu, Daniel Levy, Mai Anh Do
  • Publication number: 20200306298
    Abstract: A method for treating and/or mitigating a respiratory condition in an equine patient. The method comprises administering a blood product to the equine patient via localized delivery to the lungs. The blood product is produced by pre-treating at least one donor horse with a diet and immunization regime for at least one month before collecting the blood from the donor horse and processing it to make the blood product. The pre-treatment diet comprises feeding the donor horse a combined amount of EPA and DHA of at least 4.25 mg/kg horse/day with the EPA:DHA ratio ranging from 1:5-5:1 and alfalfa hay. The immunization regimen comprises immunizing the donor horse with Rhodooccus equi.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: TAMMI SUE EPP, JEFFERY SCOTT PENDERGRAFT, DONALD E. MYERS, WILLIAM G. SKELLY, NICOLE GREEN
  • Publication number: 20200306299
    Abstract: The present disclosure provides a system for mimicking the secondary lymphoid organs where suspension cells (e.g., T cells) are expanded; methods of expanding, activating, and transfecting the suspension cells in the synthetic microenvironment, and suspension cells produced by such systems and methods.
    Type: Application
    Filed: October 20, 2017
    Publication date: October 1, 2020
    Inventors: Krishnendu Roy, Nate Dwarshuis, Ranjna Madan-lala, Kyung-Ho Roh, Hannah Kathryn Wilson
  • Publication number: 20200306300
    Abstract: The present application relates to methods of activating a NK cells in vitro, ex vivo, and/or in vivo by an osteoclast cell (OC) and/or a dendritic cell, and methods of treating disease using these activated NK cells.
    Type: Application
    Filed: February 15, 2018
    Publication date: October 1, 2020
    Inventor: Anahid Jewett
  • Publication number: 20200306301
    Abstract: Polynucleotides encoding immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.
    Type: Application
    Filed: July 3, 2018
    Publication date: October 1, 2020
    Inventors: Thomas L. Andresen, Douglas S. Jones
  • Publication number: 20200306302
    Abstract: Described herein are methods for treating or preventing leukemias with NK-92 cells. In particular, provided are methods of treating or preventing leukemias by administering to a patient one or more doses of NK-92 cells for killing remnant (also referred to as residual) leukemia cells and/or leukemia stem cells. In various embodiments, NK-92 cells are administered to a patient to treat and/or prevent leukemia that is refractory or resistant, or has relapsed in a patient who is recovering from treatment for leukemia under conventional therapies.
    Type: Application
    Filed: August 3, 2018
    Publication date: October 1, 2020
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Tien Lee
  • Publication number: 20200306303
    Abstract: The present invention relates to a method able to enhance survival and functionality of anti-tumor or anti-viral immune cells through overexpression of Akt molecules in the cells. Akt signaling prevented the expression of immune checkpoints and therefore rescued antigen-specific cytotoxic T lymphocytes from exhaustion in immunosuppressive microenvironment.
    Type: Application
    Filed: October 1, 2018
    Publication date: October 1, 2020
    Inventors: Li-Rung HUANG, Shu-Ching HSU
  • Publication number: 20200306304
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Avery D. Posey, Carl H. June
  • Publication number: 20200306305
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Inventors: Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
  • Publication number: 20200306306
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 1, 2020
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Publication number: 20200306307
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 1, 2020
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Publication number: 20200306308
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
  • Publication number: 20200306309
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Branden Moriarity, Beau Webber, David Largaespada, Modassir Choudhry, Steven A. Rosenberg
  • Publication number: 20200306310
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Publication number: 20200306311
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
  • Publication number: 20200306312
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Publication number: 20200306313
    Abstract: Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Senlin LI, Robert A. CLARK, Cang CHEN
  • Publication number: 20200306314
    Abstract: The present invention is related to a method for treating and/or preventing Alzheimer's disease, especially using mitochondria for treatment and/or prevention of Alzheimer's disease.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Inventors: Han-Chung CHENG, Chi-Tang TU, Chih-Kai HSU
  • Publication number: 20200306315
    Abstract: Therapeutic chondrisome compositions and related methods are described.
    Type: Application
    Filed: November 30, 2016
    Publication date: October 1, 2020
    Inventors: Geoffrey von Maltzahn, John Miles Milwid, Michael Mee, Jacob Rosenblum Rubens, David Chess, Kyle Trudeau, Kiana Mahdaviani, Jacob Feala
  • Publication number: 20200306316
    Abstract: Therapeutic chondrisome and mitoplast compositions and related methods are described.
    Type: Application
    Filed: November 30, 2016
    Publication date: October 1, 2020
    Inventors: Geoffrey von Maltzahn, John Miles Milwid, Michael Mee, Jacob Rosenblum Rubens, David Chess, Kyle Trudeau, Kiana Mahdaviani, Jacob Feala
  • Publication number: 20200306317
    Abstract: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.
    Type: Application
    Filed: April 27, 2020
    Publication date: October 1, 2020
    Inventors: Robert J. HARMAN, JR., Theodore T. SAND
  • Publication number: 20200306318
    Abstract: Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.
    Type: Application
    Filed: January 22, 2020
    Publication date: October 1, 2020
    Applicant: PLURISTEM LTD.
    Inventor: ABERMAN Zami
  • Publication number: 20200306319
    Abstract: Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.
    Type: Application
    Filed: June 9, 2020
    Publication date: October 1, 2020
    Applicant: PLURISTEM LTD.
    Inventors: Raphael GORODETSKY, Zami ABERMAN
  • Publication number: 20200306320
    Abstract: Sperm can be separated by nonlethal methods in a sorting track that into cubicles having different cubicle characteristics. A test sample of sperm from selected cubicles can be sacrificed to determine their prevalent genetic characteristics. The visually identifiable characteristics of sperm from the test samples can also be correlated with prevalent genetic characteristics. A living sperm, sharing selected genetic characteristics, can be selected from remaining sperm having similar identifiable characteristics in a respective cubicle and used for fertilizing an egg.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 1, 2020
    Inventor: Anya L. Getman
  • Publication number: 20200306321
    Abstract: The invention relates to the use of a composition comprising at least one strain of Bacillus subtilis, for the degradation of mycotoxins.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 1, 2020
    Inventors: Michel LAYUS, Alexandre BRAME
  • Publication number: 20200306322
    Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.
    Type: Application
    Filed: January 30, 2020
    Publication date: October 1, 2020
    Inventors: Remy Burcelin, Didier CARCANO, Sampo LAHTINEN, Lotta STENMAN, John KONHILAS
  • Publication number: 20200306323
    Abstract: The present invention relates to the use of specific strains of Lactobacillus paracasei or of a composition comprising said strains for the prevention and/or treatment of a physiopathological condition related to/associated with Clostridium difficile infection, preferably intestinal infections, or so-called CD-associated disease (CDAD) or CD infection (CDI).
    Type: Application
    Filed: September 12, 2018
    Publication date: October 1, 2020
    Inventor: Andrea BIFFI
  • Publication number: 20200306324
    Abstract: The present invention provides a method of reducing body fat, comprising administering a composition comprising an effective amount of Lactobacillus paracasei or a metabolite thereof to a subject in need thereof. The Lactobacillus paracasei or the metabolite thereof can effectively convert the fatty acid into conjugated linoleic acid, inhibit the accumulation of fat and promote the decomposition of fat in fat cells, and can effectively reduce the percentage of body fat, waist circumference, and hip circumference, and simultaneously increase the muscle mass of the subject.
    Type: Application
    Filed: December 31, 2019
    Publication date: October 1, 2020
    Inventors: Yung-Hsiang Lin, Chu-Han Huang, Cheng-Yu Ho
  • Publication number: 20200306325
    Abstract: The present disclosure provides methods and composition for preventing and/or treating oral diseases or conditions (e.g., halitosis, a periodontal disease, or caries) in a subject (e.g., a human) in need thereof. The compositions described herein may allow for oral administration, e.g., using a tablet dosage form. The compositions may comprise one or more probiotics.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 1, 2020
    Inventors: Patrick SCHWIENTEK, Kishore NANNAPANENI, David DRAKE, Jeffrey Alan BANAS
  • Publication number: 20200306326
    Abstract: The present disclosure relates to compositions and methods for the production of short chain fatty acids in the gut of a host organism. The compositions of the disclosure are synbiotic compositions comprising the microorganism Lactobacillus rhamnosus. The present method relates to an in silico method for the rational design of synbiotic compositions.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Inventors: SUCHETA GOKHALE, ANIRBAN BHADURI
  • Publication number: 20200306327
    Abstract: The invention relates to novel bacteria of the species Lactobacillus plantarum and to compositions comprising Lactobacillus plantarum, and methods and uses of said compositions for preventing and/or treating mental illness, symptoms affecting mental health and/or conditions associated with chronic stress, in a mammal. The invention can be applied in restoring, maintaining, and/or promoting mental (including cognitive) health and has potential applications, inter alia, in the area of dietary and food supplements, medicaments and pharmaceuticals.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 1, 2020
    Inventors: Lotta Stenman, Markus Lehtinen, Yuejian Mao
  • Publication number: 20200306328
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: October 30, 2019
    Publication date: October 1, 2020
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
  • Publication number: 20200306329
    Abstract: The present invention is a process for producing various types of cannabis extract from harvested cannabis. A quantity of harvested cannabis, which typically includes the inflorescence, floral leaves, and small stems of a flowering cannabis plants, is pre-frozen. The harvested cannabis is first subjected to cryogenic grinding to produce pulverized cannabis. The pulverized cannabis is then subjected to alcohol extraction to produce an initial cannabis extract, which can be subjected to one of several forms of further processing according to the desired chemical profile of the final product. The initial cannabis extract may then be subjected to chemical processing that promote the conversion of THCA to ?9 THC; the conversion of THCVA to THCV; the conversion of THCA to cannabinol (“CBN”); or the conversion of THCA to ?8-THC.
    Type: Application
    Filed: November 5, 2019
    Publication date: October 1, 2020
    Inventor: James Castillo
  • Publication number: 20200306330
    Abstract: A method for preventing or treating at least one of depression and anxiety disorder according to an embodiment of the present invention includes administering to a subject in need thereof a composition having an extract of Fraxinus rhynchophylla as an effective ingredient. By having an effect of improving depressive behavior and low physical activity shown in an animal model with induced anxiety and depression, reducing the level of cortisol, increasing the level of serotonin, and also increasing the expression amount of pCERB, BDNF, and mBDNF proteins in hippocampal tissues, the compositions can be advantageously used for developing a functional health food product or a pharmaceutical product for ameliorating or treating the depression and anxiety disorder.
    Type: Application
    Filed: October 15, 2018
    Publication date: October 1, 2020
    Inventors: Mi Young LEE, Yu Ri KIM, Bo-Kyung PARK, Young Hwa KIM
  • Publication number: 20200306331
    Abstract: This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 1, 2020
    Inventors: Shwu-Huey Liu, Zaoli Jiang, Yung-Chi Cheng